Adding irradiation before transplant improves long-term results and should change practice
Scleroderma with internal organ involvement is a debilitating and lethal autoimmune disorder with few effective treatments. But a study led by Duke Health researchers has found new cause for optimism using an aggressive stem cell transplant regimen.
The researchers, publishing in the Jan. 4 issue of the New England Journal of Medicine, found significantly improved survival among patients with a severe form of scleroderma who underwent chemotherapy, whole body radiation and a stem cell transplant. Patients also had less need for immune suppressant drugs after transplant.
“Scleroderma hardens the skin and connective tissues and in its severe form leads to fatal organ failure, most often the lungs” said lead author Keith Sullivan, M.D., James B. Wyngaarden Professor of Medicine and Cellular Therapy at Duke. “In these severe cases, conventional drug therapies are not very effective long-term, so new approaches are a priority.”
Earlier publications suggested that stem cell transplant might be a viable treatment, using less intensive treatment without irradiation. These studies showed that reduced-intensity stem cell transplant improved survival, but the disease often returned and patient safety remained a concern. As a result, conventional immunosuppressive drug treatment remained the standard of care in the U.S.
In the current study, Sullivan and colleagues developed a transplant conditioning regimen that included high-dose chemotherapy plus whole-body radiation to fully wipe out the patient’s defective immune-forming system, with the aim of improving survival and diminishing the effects of the disease. They limited radiation by shielding patients’ kidneys and lungs while repopulating the blood and immune system.
Thirty-six scleroderma patients were randomly assigned to receive transplant. The regimen was designed to destroy the patients’ defective autoreactive immune system and replace it with their own blood stem cells that had been removed and treated to eliminate self-reacting lymphocytes.
For comparison, 39 additional patients were randomized to receive 12 monthly intravenous injections of cyclophosphamide, a conventional immune suppressing treatment for severe scleroderma.
“These results show that individuals with poor-prognosis scleroderma can improve and live longer and that these advances appear durable.”
The study was conducted over a 10-year period at 26 universities in the United States and Canada. The primary study endpoint at 54 months was a global rank composite score based on a hierarchy of scleroderma features including survival, organ function, quality of life and skin hardening. Results showed significant benefit with transplant: 67 percent of 1,404 pairwise comparisons favored transplant vs. 33 percent favoring cyclophosphamide.
By study endpoint, fewer transplant recipients resumed use of anti-scleroderma drugs (9 percent vs. 44 percent of controls). Overall survival at 72 months was 86 percent after transplant vs. 51 percent after cyclophosphamide — a highly significant benefit.
“These results show that individuals with poor-prognosis scleroderma can improve and live longer and that these advances appear durable,” Sullivan said.
Treatment-related mortality at the study endpoint of 54 months was 3 percent among transplant recipients while cyclophosphamide recipients had no treatment-related deaths. In the short term, transplant recipients also had more serious side effects, such as low blood counts and infections.
“Patients and their doctors should carefully weigh the pros and cons of intensive treatment with stem cell transplant, but this may hopefully set a new standard in this otherwise devastating autoimmune disease,” Sullivan said. “These advances show the value of medical research and clinical trials in finding better therapies to advance health.”
The Latest on: Stem cell transplant
[google_news title=”” keyword=”stem cell transplant” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Frailty Can Lengthen Post-Transplant Hospital Stayson February 29, 2024 at 4:00 pm
Consulting physical therapy early on and speaking up to the health care team can help patients with blood cancer be more prepared for a hematopoietic stem cell transplant, an expert said. Patients ...
- NHS ‘fast tracks’ new therapy for stem cell patientson February 28, 2024 at 4:01 pm
Chronic graft versus host disease is diagnosed in about a third of patients who have undergone stem cell or bone marrow transplants for blood cancers.
- Toddler's mum calls stem cell donors 'superheroes'on February 27, 2024 at 10:24 pm
Oti from Saffron Walden in Essex, was diagnosed with acute myeloid leukaemia in 2022 but is cancer-free after stem cells, frozen for 12 years, were found to be a match and allowed treatment. His mum ...
- Stealthy stem cells to treat diseaseon February 27, 2024 at 4:00 pm
Researchers can now cultivate stem cells in a laboratory, transform them into specialized cell types and then transplant them into people to alleviate disease. In theory, this strategy promises an ...
- A man was cured of HIV and leukemia after stem cell transplanton February 27, 2024 at 11:13 am
If you buy through a BGR link, we may earn an affiliate commission, helping support our expert product labs. Research into stem cells has paid off as 68-year-old Paul Edmonds remains effectively cured ...
- Patient cured of HIV and leukemia is ‘extremely grateful’ 5 years after stem cell transplanton February 26, 2024 at 4:06 pm
Five years after receiving a life-changing stem cell transplant, a 68-year-old man says he’s “extremely grateful” to be essentially cured of acute myelogenous leukemia and in HIV remission. “Many City ...
- US man 'cured' of HIV, Leukaemia with trailblazing stem cell transplanton February 26, 2024 at 4:00 pm
Paul Edmonds, a 68-year-old patient, expressed his gratitude for being virtually healed of acute myelogenous leukaemia and experiencing HIV remission after undergoing a transformative stem cell ...
- Man 'cured' of HIV and leukaemia after receiving stem cells from donor with rare mutationon February 26, 2024 at 2:34 pm
Paul Edmonds, 67, has been in remission for five years after receiving groundbreaking stem cell transplant treatment at a center in California ...
- Scientists make a brand new strategy to eradicate leukemia stem cellson February 26, 2024 at 10:00 am
Discovery using lab and animal models could provide an alternative for older, sicker patients who do not qualify for stem cell transplants The method offers new hope for acute myeloid leukemia ...
- Man ‘cured’ of HIV and cancer in astonishing medical recovery after ‘groundbreaking’ stem cell transplanton February 26, 2024 at 7:16 am
A MAN was “cured” of HIV and leukaemia after a “remarkable” stem cell transplant from a donor with a rare genetic mutation. Paul Edmonds, 67, was diagnosed with AIDS in ...
via Google News and Bing News